Low dose histone deacetylase inhibitor, depsipeptide (FR901228), promotes adenoviral transduction in human rhabdomyosarcoma cell lines

Sarcoma

Volumn 8, Issue 1, 2004, Pages 25-30

  Navid, Fariba ^a,b   Mischen, Blaine T ^a   Helman, Lee J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Adenoviral uptake; Histone deacetylase inhibitor; Rhabdomyosarcoma

Indexed keywords

ADENOVIRUS VECTOR; ALPHA5 INTEGRIN; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; DEPSIPEPTIDE; FR 901228; GREEN FLUORESCENT PROTEIN; HISTONE DEACETYLASE INHIBITOR;

ARTICLE; CANCER CELL CULTURE; CELL STRAIN RH5; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; GENE EXPRESSION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; LOW DRUG DOSE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHABDOMYOSARCOMA;

EID: 1842453727     PISSN: 1357714X     EISSN: None     Source Type: Journal    
DOI: 10.1080/13577140410001679220     Document Type: Article

References (27)

1. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, Horwitz MS, Crowell RL, Finberg RW. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997; 275: 1320-3.
2. Arnberg N, Edlund K, Kidd AH, Wadell G. Adenovirus type 37 uses sialic acid as a cellular receptor. J Virol 2000; 74: 42-8.
3. Dechecchi MC, Tamanini A, Bonizzato A, Cabrini G. Heparan sulfate glycosaminoglycans are involved in adenovirus type 5 and 2-host cell interactions. Virology 2000; 268: 382-90.
4. Wickham TJ, Mathias P, Cheresh DA, Nemerow GR. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 1993; 73: 309-19.
5. Li E, Stupack DG, Brown SL, Klemke R, Schlaepfer DD, Nemerow GR. Association of p130CAS with phosphatidylinositol-3-OH kinase mediates adenovirus cell entry. J Biol Chem 2000; 275: 14729-35.
6. Miller CR, Buchsbaum DJ, Reynolds PN, Douglas JT, Gillespie GY, Mayo MS, Raben D, Curiel DT. Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Cancer Res 1998; 58: 5738-48.
7. Li Y, Pong RC, Bergelson JM, Hall MC, Sagalowsky AI, Tseng CP, Wang Z, Hsieh JT. Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. Cancer Res 1999; 59: 325-30.
8. Kitazono M, Goldsmith ME, Aikou T, Bates S, Fojo T. Enhanced adenovirus transgene expression in malignant cells treated with the histone deacetylase inhibitor FR901228. Cancer Res 2001; 61: 6328-30.
9. Gripe TP, Dunphy EJ, Holub AD, Saini A, Vasi NH, Mahller YY, Collins MH, Snyder JD, Krasnykh V, Curiel DT, Wickham TJ, DeGregori J, Bergelson JM, Currier MA. Fiber knob modifications overcome low, heterogeneous expression of the coxsackievirus-adenovirus receptor that limits adenovirus gene transfer and oncolysis for human rhabdomyosarcoma cells. Cancer Res 2001; 61: 2953-60.
10. Fasbender A, Zabner J, Chillon M, Moninger TO, Puga AP, Davidson BL, Welsh MJ. Complexes of adenovirus with polycationic polymers and cationic lipids increase the efficiency of gene transfer in vitro and in vivo. J Biol Chem 1997; 272: 6479-89.
11. Kaplan JM, Pennington SE, St George JA, Woodworth LA, Fasbender A, Marshall J, Cheng SH, Wadsworth SC, Gregory RJ, Smith AE. Potentiation of gene transfer to the mouse lung by complexes of adenovirus vector and polycations improves therapeutic potential. Hum Gene Ther 1998; 9: 1469-79.
12. Lanuti M, Kouri CE, Force S, Chang M, Amin K, Xu K, Blair I, Kaiser L, Albelda S. Use of protamine to augment adenovirus-mediated cancer gene therapy. Gene Ther 1999; 6: 1600-10.
13. Dunphy EJ, Redman RA, Herweijer H, Gripe TP. Reciprocal enhancement of gene transfer by combinatorial adenovirus transduction and plasmid DNA transfection in vitro and in vivo. Hum Gene Ther 1999; 10: 2407-17.
14. Nakajima H, Kim YB, Terano H, Yoshida M, Horinouchi S. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp Cell Res 1998; 241: 126-33.
15. Ueda H, Nakajima H, Hori Y, Fujita T, Nishimura M, Goto T, Okuhara M. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. J Antibiot (Tokyo) 1994; 47: 301-10.
16. Ueda H, Nakajima H, Hori Y, Goto T, Okuhara M. Action of FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum no. 968, on Ha-ras transformed NTH3T3 cells. Biosci Biotechnol Biochem 1994; 58: 1579-83.
17. Ueda H, Manda T, Matsumoto S, Mukumoto S, Nishigaki F, Kawamura I, Shimomura K. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice. J Antibiot (Tokyo) 1994; 47: 315-23.
18. Dion LD, Goldsmith KT, Tang DC, Engler JA, Yoshida M, Garver RI Jr. Amplification of recombinant adenoviral transgene products occurs by inhibition of histone deacetylase. Virology 1997; 231: 201-9.
19. Tang DC, Johnston SA, Carbone DP. Butyrate-inducible and tumor-restricted gene expression by adenovirus vectors. Cancer Gene Ther 1994; 1: 15-20.
20. Gaetano C, Catalano A, Palumbo R, Illi B, Orlando G, Ventoruzzo G, Serino F, Capogrossi MC. Transcriptionally active drugs improve adenovirus vector performance in vitro and in vivo. Gene Ther 2000; 7: 1624-30.
21. Kitazono M, Rao VK, Robey R, Aikou T, Bates S, Fojo T, Goldsmith ME. Histone deacetylase inhibitor FR901228 enhances adenovirus infection of hematopoietic cells. Blood 2002; 99: 2248-51.
22. Houghton JA, Houghton PJ, Webber BL. Growth and characterization of childhood rhabdomyosarcomas as xenografts. J Natl Cancer Inst 1982; 68: 437-43.
23. Kalebic T, Judde JG, Velez-Yanguas M, Knutsen T, Helman LJ. Metastatic human rhabdomyosarcoma: molecular, cellular and cytogenetic analysis of a novel cellular model. Invasion Metastasis 1996; 16: 83-96.
24. Felix CA, Kappel CC, Mitsudomi T, Nau MM, Tsokos M, Crouch GD, Nisen PD, Winick NJ, Helman LJ. Frequency and diversity of p53 mutations in childhood rhabdomyosarcoma. Cancer Res 1992; 52: 2243-7.
25. Denizot F, Lang R. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods 1986; 89: 271-7.
26. El-Badry OM, Romanus JA, Helman LJ, Cooper MJ, Rechler MM, Israel MA. Autonomous growth of a human neuroblastoma cell line is mediated by insulin-like growth factor II. J Clin Invest 1989; 84: 829-39.
27. Abounader R, Lal B, Luddy C, Koe G, Davidson B, Rosen EM, Laterra J. In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis. FASEB J 2002; 16: 108-10.